GO:0150036 regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0150036 describes a biological process in which endocannabinoids regulate trans-synaptic signaling to modulate synaptic transmission.
• The endocannabinoid system is highly expressed in the basal ganglia and mesolimbic reward system, where it influences motor control, motivation, and reward.
• Dysregulation of endocannabinoid signaling is implicated in neurological and psychiatric disorders such as Parkinson's disease, Huntington's disease, schizophrenia, and addiction.
• Cyclooxygenase-2 (COX-2) and its products can influence neuronal homeostasis and may interact with endocannabinoid pathways in memory and anxiety circuits.
• Key molecular players include CB1 receptors, endocannabinoid synthesizing enzymes (e.g., DAGL, NAPE-PLD), and degrading enzymes (e.g., MAGL, FAAH).
• CRISPR-based models (knockout, knock-in, overexpression) enable causal interrogation of genes regulating endocannabinoid-mediated synaptic transmission.
Description
GO:0150036, regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission, is a biological process that captures how endocannabinoids act as retrograde messengers to fine-tune synaptic communication. This process is essential for normal brain function, influencing synaptic plasticity, neurotransmitter release, and circuit excitability. Researchers study this term to understand how lipid signaling modulates neural circuits and how its disruption contributes to disease. The endocannabinoid system is particularly enriched in the basal ganglia and mesolimbic reward system, where it regulates motor and motivational behaviors. Additionally, inflammatory mediators such as cyclooxygenase-2 (COX-2) can intersect with endocannabinoid pathways, affecting neuronal homeostasis in memory and anxiety. Thus, GO:0150036 provides a framework for investigating synaptic modulation in health and disease.
regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission At A Glance
| GO ID | GO:0150036 |
|---|---|
| GO term | regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulation of synaptic transmission via endocannabinoid retrograde signaling |
| Related system | Endocannabinoid system in basal ganglia and mesolimbic reward system |
| Associated enzymes | DAGL, NAPE-PLD, MAGL, FAAH, COX-2 |
| Key receptors | CB1 receptor |
What Is GO:0150036?
This GO term refers to any process that modulates the frequency, rate, or extent of trans-synaptic signaling by endocannabinoids, thereby modulating synaptic transmission. In simpler terms, it describes how endocannabinoid molecules, released from postsynaptic neurons, travel backward across the synapse to regulate presynaptic neurotransmitter release and overall synaptic strength.
Why Is regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Important in Cell Biology?
Understanding GO:0150036 is critical because endocannabinoid-mediated synaptic modulation is a fundamental mechanism for neural circuit plasticity, and its dysregulation is linked to major neurological and psychiatric disorders, including Parkinson's disease, Huntington's disease, schizophrenia, and drug addiction. Moreover, crosstalk with inflammatory pathways such as COX-2 may influence memory and anxiety, highlighting broader implications for brain health.
• Regulates neurotransmitter release and synaptic plasticity in the brain.
• Modulates motor control through basal ganglia circuits.
• Influences reward, motivation, and addictive behaviors via the mesolimbic system.
• Implicated in Parkinson's disease and Huntington's disease pathophysiology.
• Associated with psychiatric disorders such as schizophrenia and depression.
• Interacts with inflammatory signaling (COX-2) in memory and anxiety.
• Provides targets for therapeutic development (e.g., CB1 modulators, enzyme inhibitors).
• Enables research into retrograde synaptic signaling mechanisms.
• Helps explain effects of cannabis and synthetic cannabinoids on brain function.
• Offers a basis for CRISPR-based disease modeling and drug screening.
What Happens During regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission?
Endocannabinoid Synthesis and Release
In simple terms: The postsynaptic neuron makes and releases endocannabinoid molecules on demand.
Endocannabinoids such as 2-arachidonoylglycerol (2-AG) and anandamide are synthesized in postsynaptic neurons by enzymes including DAGL and NAPE-PLD, respectively, and are released into the synaptic cleft in response to neuronal activity.
Retrograde Signaling to Presynaptic Terminals
In simple terms: Endocannabinoids travel backward to the presynaptic neuron.
Once released, endocannabinoids act as retrograde messengers, binding to CB1 receptors located on presynaptic terminals, thereby modulating neurotransmitter release.
CB1 Receptor Activation and Downstream Effects
In simple terms: CB1 receptors on the presynaptic side change how much neurotransmitter is released.
Activation of presynaptic CB1 receptors, which are Gi/o-coupled, inhibits adenylyl cyclase and voltage-gated calcium channels, and activates potassium channels, leading to reduced neurotransmitter release and altered synaptic transmission.
Endocannabinoid Degradation and Termination
In simple terms: Enzymes break down endocannabinoids to stop the signal.
Endocannabinoid signaling is terminated by enzymatic degradation: MAGL hydrolyzes 2-AG, while FAAH degrades anandamide, ensuring tight temporal control of synaptic modulation.
Integration with Other Signaling Pathways
In simple terms: Endocannabinoid signals can crosstalk with other molecules like COX-2.
Cyclooxygenase-2 (COX-2) can oxygenate endocannabinoids, producing prostaglandin-like compounds that may influence neuronal homeostasis, memory, and anxiety, thus adding another layer of regulation to synaptic transmission.
Key Genes Involved in GO:0150036 regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
The following genes and proteins are central to endocannabinoid-mediated regulation of synaptic transmission, based on their roles in synthesis, reception, degradation, and crosstalk.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CNR1 | Encodes CB1 receptor, mediates presynaptic inhibition | Target for modulating synaptic transmission; knockout models available |
| DAGLA | Diacylglycerol lipase alpha, synthesizes 2-AG | Key enzyme for 2-AG production; knockout reduces endocannabinoid signaling |
| DAGLB | Diacylglycerol lipase beta, synthesizes 2-AG | Isoform-specific roles in endocannabinoid synthesis |
| NAPEPLD | N-acyl phosphatidylethanolamine phospholipase D, synthesizes anandamide | Regulates anandamide levels; knockout alters pain and anxiety |
| MGLL | Monoacylglycerol lipase, degrades 2-AG | Inhibition elevates 2-AG; target for anti-inflammatory and analgesic drugs |
| FAAH | Fatty acid amide hydrolase, degrades anandamide | Inhibition increases anandamide; linked to pain and mood disorders |
| PTGS2 | Cyclooxygenase-2, oxygenates endocannabinoids | Crosstalk with endocannabinoid system in memory and anxiety |
| GNAI1 | Gi/o alpha subunit, mediates CB1 signaling | Downstream effector of CB1; knockout affects synaptic plasticity |
| GNAO1 | G protein alpha o subunit, mediates CB1 signaling | Enriched in neurons; mutations cause neurological disorders |
| CACNA1B | Voltage-gated calcium channel, inhibited by CB1 | CB1-mediated inhibition of Ca2+ influx reduces neurotransmitter release |
| KCNJ3 | GIRK1 potassium channel, activated by CB1 | CB1 activation increases K+ conductance, hyperpolarizing neurons |
| ADCY1 | Adenylyl cyclase 1, inhibited by CB1 | CB1-mediated inhibition of cAMP affects synaptic plasticity |
| MAPK3 | ERK1, downstream of CB1 | CB1 can activate MAPK pathways, influencing gene expression |
| MAPK1 | ERK2, downstream of CB1 | CB1-mediated ERK signaling in synaptic modulation |
| PIK3CA | PI3K catalytic subunit, downstream of CB1 | CB1 can activate PI3K/Akt signaling |
| AKT1 | Akt1, downstream of CB1 | CB1-mediated survival and plasticity signaling |
| GRM5 | mGluR5, involved in endocannabinoid synthesis | Group I mGluR activation triggers 2-AG production |
| GRM1 | mGluR1, involved in endocannabinoid synthesis | mGluR1 activation stimulates endocannabinoid release |
How Is regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Regulated?
The process of endocannabinoid-mediated synaptic modulation is regulated at multiple levels. Synthesis of endocannabinoids is activity-dependent, triggered by postsynaptic calcium increases and Gq-coupled receptor activation (e.g., mGluR1/5). Degradation by MAGL and FAAH provides temporal control. Additionally, COX-2 can oxidize endocannabinoids, generating bioactive lipids that may modulate neuronal homeostasis and behavior, as seen in memory and anxiety paradigms. CB1 receptor desensitization and internalization also regulate the duration and magnitude of signaling.
regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CNR1 | Parkinson's disease, addiction | Conditional knockout in basal ganglia neurons |
| MGLL | Neuroinflammation, pain | Knockout or point mutation to inhibit enzymatic activity |
| FAAH | Anxiety, pain | Knock-in of human variant or knockout |
| PTGS2 | Memory deficits, anxiety | Overexpression or knockout in hippocampus |
| DAGLA | Epilepsy, motor dysfunction | Knockout to reduce 2-AG synthesis |
Neurodegenerative Disorders
Altered endocannabinoid signaling in the basal ganglia contributes to motor symptoms in Parkinson's disease and Huntington's disease, where CB1 receptor availability and endocannabinoid levels are changed. Targeting enzymes like MAGL or FAAH may offer therapeutic benefits.
Psychiatric and Addictive Disorders
The mesolimbic reward system relies on endocannabinoid modulation; dysregulation is implicated in schizophrenia, depression, and drug addiction. CB1 receptor antagonists and enzyme inhibitors are explored for these conditions.
Inflammatory and Anxiety-Related Conditions
COX-2, which can metabolize endocannabinoids, influences memory and anxiety-like behaviors, suggesting that crosstalk between inflammatory and endocannabinoid pathways may contribute to neuropsychiatric symptoms.
From regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CB1 receptor affect synaptic plasticity? | CNR1 knockout mouse or CRISPR KO in neurons |
| Does a point mutation in FAAH alter anandamide levels? | FAAH point-mutation knock-in via CRISPR |
| Can overexpression of DAGLA enhance 2-AG signaling? | DAGLA overexpression in cell lines or transgenic mice |
| What is the effect of MAGL inhibition on neuroinflammation? | MAGL knockout or point mutation |
| How does COX-2 crosstalk with endocannabinoids in memory? | PTGS2 knockout or overexpression in hippocampal neurons |
| Can CRISPR library screening identify novel regulators of endocannabinoid signaling? | Genome-wide CRISPR knockout library in neuronal cell lines |
How to Study the regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Synaptic currents, release probability | Assess CB1-mediated inhibition of transmission |
| LC-MS/MS lipidomics | Endocannabinoid levels | Quantify 2-AG and anandamide in brain tissue |
| CRISPR knockout screening | Gene essentiality for endocannabinoid signaling | Identify novel regulators in neuronal cell lines |
| RNA-seq | Transcriptional changes | Profile gene expression after CB1 activation |
| Western blot | Protein expression and phosphorylation | Measure CB1 downstream signaling |
| Immunohistochemistry | Localization of CB1 and enzymes | Map expression in brain regions |
| Behavioral tests | Motor, reward, anxiety-like behaviors | Link molecular changes to phenotype |
| FRET/BRET biosensors | Real-time cAMP or calcium changes | Monitor CB1 signaling dynamics |
Electrophysiology
Patch-clamp recordings measure synaptic currents and paired-pulse ratios to assess endocannabinoid-mediated suppression of neurotransmitter release.
Lipidomics and Mass Spectrometry
Quantification of endocannabinoids (2-AG, anandamide) and their metabolites using LC-MS/MS to monitor synthesis and degradation.
CRISPR Screening
Genome-wide knockout or activation screens in neuronal cells can identify genes that regulate endocannabinoid signaling and synaptic transmission.
Behavioral Assays
Tests for motor function, reward, anxiety, and memory in genetically modified rodents link molecular changes to behavior.
How CRISPR Can Be Used to Study GO:0150036 regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
Knockout
CRISPR knockout of genes such as CNR1, DAGLA, or MGLL in cell lines or animal models can abolish endocannabinoid signaling, allowing researchers to study loss-of-function effects on synaptic transmission.
Point Mutation
Introducing precise point mutations (e.g., in FAAH active site) via CRISPR base editing or HDR can mimic human variants and reveal their impact on enzyme activity and synaptic modulation.
Knock-in
Knock-in of tagged versions (e.g., GFP-CB1) or human disease alleles enables visualization and functional analysis of endocannabinoid components in native contexts.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of DAGLA or CB1 can enhance endocannabinoid signaling, useful for gain-of-function studies.
How EDITGENE Supports regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Research
Researchers studying regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission-related genes often need to determine whether a candidate gene is causally involved in synaptic modulation or disease. EDITGENE provides tailored CRISPR solutions to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission research.
Frequently Asked Questions About regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
What is GO:0150036?
GO:0150036 is a Gene Ontology biological process term describing the regulation of trans-synaptic signaling by endocannabinoids, which modulates synaptic transmission.
What genes are involved in regulation of trans-synaptic signaling by endocannabinoid?
Key genes include CNR1 (CB1 receptor), DAGLA, DAGLB, NAPEPLD, MGLL, FAAH, and PTGS2 (COX-2).
How do endocannabinoids modulate synaptic transmission?
Endocannabinoids are released from postsynaptic neurons and bind to presynaptic CB1 receptors, inhibiting neurotransmitter release.
What diseases are associated with endocannabinoid signaling?
Parkinson's disease, Huntington's disease, schizophrenia, addiction, anxiety, and pain disorders.
What is the role of COX-2 in endocannabinoid signaling?
COX-2 can oxygenate endocannabinoids, producing bioactive lipids that influence neuronal homeostasis, memory, and anxiety.
How can CRISPR be used to study GO:0150036?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of genes involved in endocannabinoid-mediated synaptic modulation.
What are the main enzymes that synthesize endocannabinoids?
DAGL synthesizes 2-AG, and NAPE-PLD synthesizes anandamide.
What enzymes degrade endocannabinoids?
MAGL degrades 2-AG, and FAAH degrades anandamide.
What brain regions are most studied for endocannabinoid synaptic modulation?
The basal ganglia and mesolimbic reward system are key regions.
What methods are used to study endocannabinoid signaling?
Electrophysiology, lipidomics, CRISPR screening, RNA-seq, and behavioral assays.
Conclusion
GO:0150036 encapsulates a vital biological process where endocannabinoids fine-tune synaptic transmission, with profound implications for brain function and disease. Understanding its molecular players and regulatory mechanisms offers opportunities for therapeutic intervention in neurological and psychiatric disorders. CRISPR-based models and advanced screening technologies are indispensable tools for dissecting this pathway and translating findings into clinical applications.
References
- 1. López DE et al.. 2020. The Role of Brain Cyclooxygenase-2 (Cox-2) Beyond Neuroinflammation: Neuronal Homeostasis in Memory and Anxiety.. Mol Neurobiol 57(12):5167-5176 PMID: 32860157
- 2. van der Stelt M et al.. 2003. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.. Eur J Pharmacol 480(1-3):133-50 PMID: 14623357
